Allogene Therapeutics Receives FDA Orphan-Drug Designation for ALLO-605, its First TurboCAR™ T Cell Product Candidate, for the Treatment of Multiple Myeloma
April 27, 2022 08:00 ET
|
Allogene Therapeutics, Inc.
ODD Follows FDA Fast Track Designation Granted for ALLO-605 in Q2 2021ALLO-605 is in Phase 1 in the IGNITE Trial and Part of Allogene’s Multi-Pronged Strategy Targeting BCMABCMA Program Clinical...
Allogene Therapeutics Unveils Cell Forge 1, a Uniquely Designed Manufacturing Facility to Deliver AlloCAR T™ Products
April 14, 2022 08:00 ET
|
Allogene Therapeutics, Inc.
Interactive Experience Designed to Showcase the 136,000sf cGMP Facility Located in Newark, CaliforniaCell Forge 1 is Operational in Preparation for the Company’s First Pivotal Trial with ALLO-501A for...
Allogene Therapeutics Publishes Preclinical Data on ALLO-316, an AlloCAR T™ Candidate Targeting CD70 for the Treatment of Renal Cell Carcinoma, at AACR’s Annual Meeting and in Cancer Research Journal
April 13, 2022 09:00 ET
|
Allogene Therapeutics, Inc.
Data Continue to Highlight the Potential of ALLO-316 to Treat Both Solid Tumors and Hematologic MalignanciesALLO-316, in Phase 1 TRAVERSE Trial for the Treatment of Renal Cell Carcinoma, Granted Fast...
Allogene Therapeutics Announces Participation in Seven Upcoming Investor Conferences
April 12, 2022 08:30 ET
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Allogene Therapeutics Announces Preclinical Publication Highlighting Superiority of Healthy Donor-Derived Allogeneic CAR T Cells Over Patient-Derived Cells in Multiple Myeloma
March 23, 2022 08:30 ET
|
Allogene Therapeutics, Inc.
Results Demonstrated Anti-BCMA CAR T Cells Derived from Healthy Donors Had Better Immune Fitness and Killing ActivityPhase 1 AlloCAR T™ Trials Underway Evaluating ALLO-715 and ALLO-605 for the...
Allogene Therapeutics Receives FDA Fast Track Designation for its First Solid Tumor Candidate, ALLO-316 in the Treatment of Renal Cell Carcinoma
March 10, 2022 08:30 ET
|
Allogene Therapeutics, Inc.
ALLO-316 is an allogeneic CAR T therapy candidate targeting CD70, which Has Broad Potential Application Across a Variety of Solid Tumors and Hematologic MalignanciesPhase 1 TRAVERSE Trial of ALLO-316...
Allogene Therapeutics Publishes Inaugural Environmental, Social and Governance (ESG) Report
March 01, 2022 08:30 ET
|
Allogene Therapeutics, Inc.
Comprehensive Report Highlights Efforts to Advance Diversity, Equity and Inclusion, Sustainable Business Practices, and Corporate Governance SOUTH SAN FRANCISCO, Calif., March 01, 2022 (GLOBE...
Allogene Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
February 23, 2022 16:02 ET
|
Allogene Therapeutics, Inc.
AlloCAR T™ Studies Resumed and Currently Enrolling Patients Following Removal of Clinical Hold in January 2022Phase 1 Data from the ALPHA Trials in Relapsed/Refractory (RR) Non-Hodgkin Lymphoma...
Allogene Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results on February 23, 2022
February 16, 2022 08:30 ET
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Allogene Therapeutics Announces Participation in Four Upcoming Virtual Investor Conferences
January 26, 2022 08:30 ET
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...